St. Jude develops the first immunologic method to diagnose solid tumors in children.

The hospital publishes a study that shows a 50% survival rate for ALL using a combination of chemotherapy and radiation. The achievement revolutionizes leukemia therapy worldwide.

Clinicians develop a treatment that is effective for 55% of patients with neuroblastoma, the second most common solid tumor in children.

Researchers pinpoint the first two specific genetic translocations known to cause acute lymphoblasic leukemia (ALL).

Scientists find evidence that some patients have a mixture of two acute leukemias: myeloid and lymphoid.

By measuring the number of copies of the N-myc gene in neuroblastoma patients, St. Jude researchers individualize chemotherapy for those children.

The Pediatric AIDS Clinical Trials Group publishes a paper on reduction of maternal-infant transmission of HIV type 1 with zidovudine treatment.

Scientists identify a genetic defect that can predispose pediatric leukemia patients to secondary brain tumors.

Researchers find that cranial artery damage in patients with sickle cell disease may be reversed by bone marrow transplantation.

Scientists unveil a genetic screening technique that uses microarray chips to diagnose and treat ALL while improving diagnostic accuracy and identifying new prognostic details.

A St. Jude study that compares long-term outcomes of children treated for ALL shows Black children do as well as white children if given equal access to the latest treatments.

Researchers find certain traits inherited from parents can reduce the effectiveness of some chemotherapy drugs in children with ALL.

Investigators discover a specific pattern of gene expression in leukemic cells that links to their resistance to anti-leukemic drugs. The discovery helps explain why standard therapies fail to cure about 20% of children with ALL.

Subtypes of medulloblastoma, which was previously thought to be one disease, are defined.

Scientists identify the specific cell that causes retinoblastoma, disproving a long-held theory.

St. Jude is designated as a National Cancer Institute Comprehensive Cancer Center, making St. Jude the first and only pediatric cancer center to receive this distinction.

An initial study from St. Jude researchers demonstrates preventative antibiotics can reduce the potential for infection in patients with acute myeloid leukemia (AML).

The most comprehensive analysis yet of the genome of childhood acute myeloid leukemia finds only a few mistakes in the genetic blueprint, indicating the cancer arises from just a few missteps.

Acute myeloid leukemia survival rates rise to 71% for children treated on a St. Jude protocol.

The Pediatric Cancer Genome Project identifies drugs that enhance oxidative stress as a possible treatment against rhabdomyosarcoma, the most common pediatric soft-tissue tumor.

A study from the Pediatric Cancer Genome Project suggests that comprehensive genomic screening may be warranted for all pediatric cancer patients, not just those with family histories of cancer.

St. Jude researchers and clinicians show the use of a preventative antibiotic treatment during the initial phase of chemotherapy lowers infection risk, broadens protection, and reduces Clostridium difficile infection in patients with acute lymphoblastic leukemia (ALL).

St. Jude is designated as the first World Health Organization Collaborating Center for Childhood Cancer. The collaboration is a worldwide effort to advance cure rates to at least 60% in children with six of the most common cancers by 2030.

St. Jude scientists identify how the SARS-CoV-2 virus activates inflammatory cell death pathways. They find that drugs already used to treat some inflammatory diseases could be repurposed for COVID-19.

By October 2021, the Global COVID-19 Observatory and Resource Center for Childhood Cancer had tracked 1,775 COVID-19 positive cases from 51 countries. This project provides an unparalleled resource for understanding how the SARS-CoV-2 virus affects children undergoing cancer treatment around the world.

Scientists from St. Jude perform the largest study yet examining drug sensitivity in pediatric ALL across genomic subtypes and its association with treatment response.

By adding a molecular anchor to chimeric antigen receptors (CARs), investigators at St. Jude increase the anti-cancer activity of cellular immunotherapies in cancer models.

St. Jude investigators reverse the cancer cell state in aggressive rhabdoid tumors by deleting or degrading the quality control protein DCAF5, marking a new paradigm in treatment possibilities.

In collaboration with University of Houston, Tufts University School of Medicine and Fox Chase Cancer Center, scientists at St. Jude develop a drug to prevent lethal lung injury from the influenza virus.